Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib.

Lastly, when attempting to replicate ORAL Surveillance’s over 65 group with cardiovascular risk factors, the sub analysis demonstrated that TOFA treated patients had a numerically higher risk for the primary composite compared to the TNFi treated patients, but this trend did not reach statistical significance with a HR of 1.24 [ 44 ]. 8.

also in 111,027 other papers